Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Novo
Novo
Activities:
Finance
X
LinkedIn
Trending Articles
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
CordenPharma & GENEPEP collaborate to leverage peptide drug substance discovery
The partnership has facilitated the expedition of the development, discovery and manufacturing of peptides for early clinical phase
ISPE announces 2024 Facility of the Year Awards category winners
The awards programme recognises pharmaceutical companies that are the 'best' in the industry for innovation, operations, digitalisation, supply chain and social impact
Tabletability, compactability and compressibility: What’s the difference?
To patients and consumers, tablets are a simple and convenient dosage form, but the science behind compressing a block of particles or granules into a single tablet can be...
Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success
Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...
Upcoming event
Making Pharmaceuticals
23–24 April 2024 | Exhibition | Coventry, UK
See all
Related Content
Finance
Novo Holdings acquires BBI Group
BBI is headquartered in South Wales and employs more than 400 employees across its sites in seven countries and four continents
Finance
Novo Holdings invests in Danish start up Bactolife
Founded in 2017, Bactolife has developed a technology based on nanobodies for management of bacterial virulence without the use of antibiotics
Finance
Novo to acquire drug development services provider Altasciences
Altasciences’ executive management team, led by CEO Chris Perkin, will continue to lead the business following the acquisition
Finance
Novo purchases Xellia Pharmaceuticals for US$700m
Xellia manufactures antibiotics for multi-drug resistant infections using fermentation-based processes
Subscribe now